Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585767 | 0.93 | OPRD1 (0.58) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4576743 | 0.92 | OPRD1 (0.57) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4616845 | 0.92 | OPRD1 (0.57) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL7617589 | 0.92 | OPRD1 (0.54) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4585705 | 0.91 | OPRD1 (0.56) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4598438 | 0.89 | OPRD1 (0.55) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4591589 | 0.89 | OPRD1 (0.54) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4585707 | 0.87 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL15080470 | 0.87 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4591360 | 0.87 | OPRD1 (0.56) | OPRD1CYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501513-B1 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | VERSI GROUP LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1450807-A4 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7030124-B2 | Method of treating depression with delta receptor agonist compounds | ARDENT PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1450807-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003037342-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | CHRND, CHRNE, CHRNA3 | OPRD1 9/4885CYP1A2 2383/4885CYP3A4 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.